<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>49-CLASS-I-ANTIARRHYTHMICS-(EXCEPT-LIDOCAINE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="CLASS I ANTIARRHYTHMICS (EXCEPT LIDOCAINE)" code="C01B-003" /></DRUG1>
<DRUG2>
<CLASS name="BETA BLOCKING AGENTS (EXCEPT ESMOLOL AND SOTALOL)" code="C07AB-001" /></DRUG2>
<DESCRIPTION>Disorders of contractility, autoregulation, and electrical conduction (suppression of the compensatory sympathetic mechanisms)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>49-CLASS-I-ANTIARRHYTHMICS-(EXCEPT-LIDOCAINE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="CLASS I ANTIARRHYTHMICS (EXCEPT LIDOCAINE)" code="C01B-003" /></DRUG1>
<DRUG2>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG2>
<DESCRIPTION>Negative inotropic effect with risk of acute decompensated heart failure 

</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
</INTERACTIONS>
